Investment area
Venture Investments
Region
North America
Date of investment
November 2022
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need.
Contact
Raymond Camahort
Partner
Departments: Venture Investments, Novo Holdings US Inc.
Raymond Camahort, Ph.D., is Partner at Novo Holdings Venture Investments. He has over 15 years of combined investment, business, and research experience, with expertise in biochemistry, genetics, and gene therapy/editing.
Prior to joining Novo Ventures, Ray worked in business development at the Harvard University Office of Technology Development where his role was to help facilitate commercialization of technologies developed in the chemistry and stem cell/regenerative biology departments.
Ray has served on the Board of Directors of numerous companies, including Ray Therapeutics, Arcellx, Inspirna, iECURE, Riva Therapeutics, and OnCusp Therapeutics. He completed a National Institute of Health post-doctoral training fellowship at Harvard University and was a pre-doctoral fellow at the Stowers Institute for Medical Research in Kansas City, Missouri. He holds a Ph.D. from the University of Kansas in biochemistry and molecular biology and a B.S. in biological sciences from the University of California Santa Barbara.
